These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32020216)

  • 1. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
    Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
    Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
    Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
    J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.
    Xu J; Huo D; Chen Y; Nwachukwu C; Collins C; Rowell J; Slamon DJ; Olopade OI
    Breast Cancer Res Treat; 2010 Apr; 120(3):593-601. PubMed ID: 19466541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
    Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
    Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,6-Dihydroxyflavone regulates microRNA-34a through DNA methylation.
    Peng X; Chang H; Chen J; Zhang Q; Yu X; Mi M
    BMC Cancer; 2017 Sep; 17(1):619. PubMed ID: 28870206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer.
    Good CR; Panjarian S; Kelly AD; Madzo J; Patel B; Jelinek J; Issa JJ
    Cancer Res; 2018 Aug; 78(15):4126-4137. PubMed ID: 29891505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
    Kawachi A; Yamashita S; Okochi-Takada E; Hirakawa A; Tsuda H; Shimomura A; Kojima Y; Yonemori K; Fujiwara Y; Kinoshita T; Ushijima T; Tamura K
    Breast Cancer Res Treat; 2020 Jun; 181(2):323-329. PubMed ID: 32314111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting DNA methylation for treating triple-negative breast cancer.
    Yu J; Zayas J; Qin B; Wang L
    Pharmacogenomics; 2019 Nov; 20(16):1151-1157. PubMed ID: 31755366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Activation of
    Donovan MG; Selmin OI; Doetschman TC; Romagnolo DF
    Nutrients; 2019 Oct; 11(11):. PubMed ID: 31652854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
    Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
    Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer.
    Lønning PE; Nikolaienko O; Pan K; Kurian AW; Eikesdal HP; Pettinger M; Anderson GL; Prentice RL; Chlebowski RT; Knappskog S
    JAMA Oncol; 2022 Nov; 8(11):1579-1587. PubMed ID: 36074460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin up-regulates phosphatase and tensin homologue deleted on chromosome 10 through microRNA-mediated control of DNA methylation--a novel mechanism suppressing liver fibrosis.
    Zheng J; Wu C; Lin Z; Guo Y; Shi L; Dong P; Lu Z; Gao S; Liao Y; Chen B; Yu F
    FEBS J; 2014 Jan; 281(1):88-103. PubMed ID: 24138392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curcumin-Mediated Reversal of p15 Gene Promoter Methylation: Implication in Anti-Neoplastic Action against Acute Lymphoid Leukaemia Cell Line.
    Sharma V; Jha AK; Kumar A; Bhatnagar A; Narayan G; Kaur J
    Folia Biol (Praha); 2015; 61(2):81-9. PubMed ID: 26333125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of SNCG, S100A4, S100A9 and LCN2 gene expression and DNA methylation in bladder cancer.
    Dokun OY; Florl AR; Seifert HH; Wolff I; Schulz WA
    Int J Cancer; 2008 Dec; 123(12):2798-807. PubMed ID: 18803290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
    Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
    Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.
    Wei M; Grushko TA; Dignam J; Hagos F; Nanda R; Sveen L; Xu J; Fackenthal J; Tretiakova M; Das S; Olopade OI
    Cancer Res; 2005 Dec; 65(23):10692-9. PubMed ID: 16322213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer.
    Umeh-Garcia M; O'Geen H; Simion C; Gephart MH; Segal DJ; Sweeney CA
    Br J Cancer; 2022 Aug; 127(3):436-448. PubMed ID: 35440669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.
    Tan X; Peng J; Fu Y; An S; Rezaei K; Tabbara S; Teal CB; Man YG; Brem RF; Fu SW
    Breast Cancer Res; 2014 Sep; 16(5):435. PubMed ID: 25228385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
    Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
    Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.